SCHEMBL6778635

SCHEMBL6778635

CCOC(=O)C(N)Cc1ccco1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.49
SLC1A3 P43003 1/20 0.44
SLC1A2 P43004 1/20 0.44
SLC1A1 P43005 1/20 0.44
ALOX5 P09917 1/20 0.44
TSHR P16473 2/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
KDM4E B2RXH2 2/20 0.42
TRPM8 Q7Z2W7 1/20 0.41
ATM Q13315 1/20 0.41
HSD17B10 Q99714 3/20 0.41
POLB P06746 2/20 0.41
HPGD P15428 2/20 0.41
TP53 P04637 1/20 0.41
USP2 O75604 2/20 0.41
MAPT P10636 2/20 0.41
LMNA P02545 1/20 0.41
MEN1 O00255 1/20 0.40
GLA P06280 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL6777275 0.98 ALDH1A1 (0.47) ALDH1A1SLC1A3SLC1A2SLC1A1ALOX5
SCHEMBL5224032 0.86 ALDH1A1 (0.52) ALDH1A1SLC1A3SLC1A2SLC1A1ALOX5
SCHEMBL12864431 0.86 ALDH1A1 (0.52) ALDH1A1SLC1A3SLC1A2SLC1A1ALOX5
Hydrochloric Acid SCHEMBL4249637 0.84 ALDH1A1 (0.51) ALDH1A1SLC1A3SLC1A2SLC1A1ALOX5
SCHEMBL24591314 0.82 CTSS (0.49) ALDH1A1SLC1A3SLC1A2SLC1A1ALOX5
SCHEMBL24591312 0.82 CTSS (0.49) ALDH1A1SLC1A3SLC1A2SLC1A1ALOX5
SCHEMBL31290369 0.81 ALDH1A1 (0.50) ALDH1A1SLC1A3SLC1A2SLC1A1ALOX5
SCHEMBL10926891 0.80 ALDH1A1 (0.50) ALDH1A1SLC1A3SLC1A2SLC1A1ALOX5
SCHEMBL12240912 0.80 ALDH1A1 (0.50) ALDH1A1SLC1A3SLC1A2SLC1A1ALOX5
SCHEMBL2668227 0.79 ALDH1A1 (0.46) ALDH1A1TSHRSMN1; SMN2L3MBTL1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12612411-B1 Imidazopyrazine derivatives, process for preparation thereof, and their uses as luciferins INSTITUT PASTEUR (FR) 2026-04-28 US disclosed
US-12576164-B2 Imidazopyrazine derivatives, process for preparation thereof, and their uses as luciferins INSTITUT PASTEUR (FR) 2026-03-17 US disclosed
EP-3964501-B1 IMIDAZOPYRAZINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, AND THEIR USES AS LUCIFERINS PASTEUR INSTITUT (FR) 2024-09-04 EP disclosed
US-20240197923-A1 IMIDAZOPYRAZINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, AND THEIR USES AS LUCIFERINS INSTITUT PASTEUR (FR) 2024-06-20 US disclosed
US-11938199-B2 Imidazopyrazine derivatives, process for preparation thereof, and their uses as luciferins INSTITUT PASTEUR (FR) 2024-03-26 US disclosed
EP-3964501-A1 IMIDAZOPYRAZINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, AND THEIR USES AS LUCIFERINS INSTITUT PASTEUR (FR) 2022-03-09 EP disclosed
EP-3615516-B1 IMIDAZOPYRAZINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, AND THEIR USES AS LUCIFERINS PASTEUR INSTITUT (FR) 2021-11-17 EP disclosed
US-20200129644-A1 IMIDAZOPYRAZINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, AND THEIR USES AS LUCIFERINS INSTITUT PASTEUR (FR) 2020-04-30 US disclosed
EP-3615516-A1 IMIDAZOPYRAZINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, AND THEIR USES AS LUCIFERINS Institut Pasteur (FR) 2020-03-04 EP disclosed
WO-2018197727-A1 IMIDAZOPYRAZINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, AND THEIR USES AS LUCIFERINS INSTITUT PASTEUR (FR) 2018-11-01 WO disclosed
US-9233913-B2 Amino acid derivatives for the treatment of neuropathic pain Kong, Xianqi (CA) 2016-01-12 US disclosed
US-9233913-B2 Amino acid derivatives for the treatment of neuropathic pain Kong, Xianqi (CA) 2016-01-12 US disclosed
US-20140171507-A1 AMINO ACID DERIVATIVES FOR THE TREATMENT OF NEUROPATHIC PAIN Kong, Xianqi (CA) 2014-06-19 US disclosed
US-20140171507-A1 AMINO ACID DERIVATIVES FOR THE TREATMENT OF NEUROPATHIC PAIN Kong, Xianqi (CA) 2014-06-19 US disclosed
US-20120208876-A1 AMINO ACID DERIVATIVES FOR THE TREATMENT OF NEUROPATHIC PAIN Kong, Xianqi (CA) 2012-08-16 US disclosed
US-20120208876-A1 AMINO ACID DERIVATIVES FOR THE TREATMENT OF NEUROPATHIC PAIN Kong, Xianqi (CA) 2012-08-16 US disclosed
WO-2010127439-A1 AMMO ACID DERIVATIVES FOR THE TREATMENT OF NEUROPATHIC PAIN BELLUS HEALTH (INTERNATIONAL) LIMITED (CH) 2010-11-11 WO disclosed
US-6831199-B1 In order to avoid bleeding side-effects when treating the conditions associated with integrin alpha v beta 3, it is beneficial to have compounds which are selective antagonists for alpha v beta 3 versus alpha IIb beta 3 G. D. SEARLE & CO. 2004-12-14 US disclosed
EP-0850221-B1 META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS SEARLE & CO (US) 2001-07-18 EP disclosed
US-6028223-A AN INTEGRIN ANTAGONISTS TREATING BONE DISORDER, PERIODONTAL DISEASE, OSTEOPOROSIS, HUMORAL HYPERCALCEMIA OF MALIGNANCY, PAGET'S DISEASE, TUMOR ANGIOGENESIS, DIABETIC RETINOPATHY, ARTHRITIS, SMOOTH MUSCLE CELL MIGRATION AND RESTENOSIS G. D. SEARLE & CO. (US) 2000-02-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11938199-B2 Imidazopyrazine derivatives, process for preparation thereof, and their uses as luciferins NISCH, HLCS, CYP3A5 ALDH1A1 972/4885SLC1A3 4497/4885SLC1A2 4287/4885
US-20200129644-A1 IMIDAZOPYRAZINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, AND THEIR USES AS LUCIFERINS NISCH, HLCS, CYP3A5 ALDH1A1 972/4885SLC1A3 4497/4885SLC1A2 4287/4885
US-12576164-B2 Imidazopyrazine derivatives, process for preparation thereof, and their uses as luciferins LUC7L2, HLCS, LANCL1 ALDH1A1 659/4885SLC1A3 4509/4885SLC1A2 4521/4885
US-12612411-B1 Imidazopyrazine derivatives, process for preparation thereof, and their uses as luciferins LUC7L2, MRPL21, CRY1 ALDH1A1 1484/4885SLC1A3 3928/4885SLC1A2 4026/4885
US-20140171507-A1 AMINO ACID DERIVATIVES FOR THE TREATMENT OF NEUROPATHIC PAIN GAP43, OPRL1, NGF ALDH1A1 2327/4885SLC1A3 10/4885SLC1A2 5/4885
US-20240197923-A1 IMIDAZOPYRAZINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, AND THEIR USES AS LUCIFERINS NISCH, HLCS, CYP3A5 ALDH1A1 972/4885SLC1A3 4497/4885SLC1A2 4287/4885
US-20120208876-A1 AMINO ACID DERIVATIVES FOR THE TREATMENT OF NEUROPATHIC PAIN GAP43, OPRL1, NGF ALDH1A1 2327/4885SLC1A3 10/4885SLC1A2 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.